Skip to main content

Table 3 Most common adverse events following the Common Terminology Criteria for Adverse Events (CTCAE 3.0)

From: Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

GradesNeurotoxicityAlopeciaAstheniaThrombocytopeniaAnaemiaNeutropeniaOral MucositisHepatotoxicity
117 (18.5%)13 (14.1%)36 (39.1%)5 (5.4%)17 (18.5%)4 (4.3%)10 (10.9%)15 (16.3%)
218 (19.6%)11 (12%)37 (40.2%)2 (2.2%)6 (6.5%)6 (6.5%)3 (3.3%)2 (2.2%)
37 (7.6%)9 (9.8%)1 (1.1%)09 (9.8%)1 (1.1%)2 (2.2%)
4000010 (10.9%) a00
  1. a Nine out of ten had febrile neutropenia